AVCT — Avacta Share News
0.000.00%
Last trade - 00:00- £318.31m
- £317.90m
- £0.11m
Issue of Equity and Total Voting Rights
Brief: Avacta Therapeutics Says Ava6000 Phase 1 Trial Showed Tumor Shrinkage In Salivary Gland Cancer Patients
Avacta Announces Data from AVA6000 Phase 1 trial
Brief: Avacta Group Appoints Brian Hahn As CFO
Avacta Appoints Chief Financial Officer
Europe Research Roundup: AJ Bell, Frequentis AG, Sage Group
Avacta Reports Pipeline Avances at EORTC
Issue of Equity and Total Voting Rights
Brief: Avacta Group Says Addition Of, AVA6103 And AVA7100, To Its Pipeline Of pre|CISION Enabled Drug Conjugates
Brief: Avacta Group Strengthens Executive Team With Appointment Of Michelle Morrow, PhD As Chief Scientific Officer
Brief: Avacta Group Explores Dual Listing On Nasdaq
Brief: Avacta H1 Adjusted EBITDA GBP -11.098 Million
Interim Results
Brief: Avacta Reports Updated Phase 1 Clinical Data Of Ava6000 Demonstrating Multiple Ongoing, Durable Responses In Solid Tumors
Notice of Results
Avacta to present clinical data at ESMO Congress
Director/PDMR Shareholdings and TVR
Brief: Avacta Group Says Second Cohort In Ava6000 Phase 1 Arm 2 Completed, Patient Dosing Ongoing In Cohort Three
AGM Business Update